Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet.
Business Wire › September 13, 2009
Linked as:
Extract
Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet.
Important Findings From First of Two Phase III Studies of Darusentan for Resistant Hypertension
FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company's once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that ...See the full content of this document
Sponsored links
